Literature DB >> 6416839

Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators.

J P Golder, R W Stephens.   

Abstract

Culture supernatants from monolayers of human peripheral monocytes strongly inhibited colorimetric assays of urokinase in which plasmin was measured by esterolysis. This inhibitory activity of monocyte culture supernatant was enhanced after culture with muramyl dipeptide. Inhibition was specific for plasminogen activators of Mr 52 000 and 36 000, as shown by three methods: (1) inhibition of plasminogen-dependent fibrinolysis; (2) inhibition at the level of plasminogen activation in a colorimetric assay; (3) the irreversible loss of plasminogen-activating activity, as evidenced by electrophoresis, after preincubation with culture media. The factor responsible for this inactivation (which we propose to call minactivin) had an apparent Mr of 66 000 on Sephacryl S300 gel chromatography and interacted with enzyme in a biphasic manner: a rapid partial inhibition (reversible by sodium dodecyl sulphate) was followed by slow inactivation (irreversible by sodium dodecyl sulphate). It is proposed that secretion of minactivin by monocytes may contribute to regulation of extracellular proteolysis at sites of tissue injury.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416839     DOI: 10.1111/j.1432-1033.1983.tb07771.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  12 in total

1.  Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

Authors:  R W Stephens; H Tapiovaara; T Reisberg; J Bizik; A Vaheri
Journal:  Cell Regul       Date:  1991-12

2.  Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture.

Authors:  F Dubor; A M Dosne; L A Chedid
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

3.  Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.

Authors:  H A Chapman; O L Stone
Journal:  Biochem J       Date:  1985-08-15       Impact factor: 3.857

Review 4.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

5.  Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor.

Authors:  T M Antalis; M A Clark; T Barnes; P R Lehrbach; P L Devine; G Schevzov; N H Goss; R W Stephens; P Tolstoshev
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

Review 6.  Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.

Authors:  J Loscalzo
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

7.  Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.

Authors:  L R Lund; A Riccio; P A Andreasen; L S Nielsen; P Kristensen; M Laiho; O Saksela; F Blasi; K Danø
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

8.  Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.

Authors:  D Belin; A Wohlwend; W D Schleuning; E K Kruithof; J D Vassalli
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

9.  Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.

Authors:  J Pöllänen; O Saksela; E M Salonen; P Andreasen; L Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1987-04       Impact factor: 10.539

10.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.

Authors:  R W Stephens; J Pöllänen; H Tapiovaara; K C Leung; P S Sim; E M Salonen; E Rønne; N Behrendt; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.